Ablukast 阿鲁司特; Ro 23-3544|cas:96566-25-5|西域试剂

Ablukast 阿鲁司特; Ro 23-3544,99.36%

产品编号：Bellancom-118958| CAS NO：96566-25-5| 分子式：C₂₈H₃₄O₈| 分子量：498.56

Ablukast（Ro 23-3544）是一种特异性和活性白三烯受体拮抗剂。Ablukast可有效降低LTC4和抗原诱导的支气管收缩。Ablukast是LTD4受体拮抗剂。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-118958	￥900.00	杭州北京（现货）
Bellancom-118958	￥2500.00	杭州北京（现货）
Bellancom-118958	￥4500.00	杭州北京（现货）
Bellancom-118958	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ablukast 阿鲁司特; Ro 23-3544

产品介绍

Ablukast (Ro 23-3544) 是一种特异性的白三烯受体拮抗剂。Ablukast 可有效减少 LTC4 和抗原诱导的支气管狭窄。Ablukast 是一种 LTD4 受体拮抗剂.

生物活性

Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction. Ablukast is LTD4 receptor antagonist.

体外研究

Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice
Dosage:	Concentrations of 0.1 , 0.5 , 1.0 and 5.0 % of Ablukast
Administration:	Applied to one of the pretreated ears 1 h after elicitation and at 24 h intervals on the following 4 days; three times daily
Result:	Effectively reduced DNFB-induced ear swelling.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice
Dosage:	Concentrations of 0.1 , 0.5 , 1.0 and 5.0 % of Ablukast
Administration:	Applied to one of the pretreated ears 1 h after elicitation and at 24 h intervals on the following 4 days; three times daily
Result:	Effectively reduced DNFB-induced ear swelling.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (200.58 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0058 mL	10.0289 mL	20.0578 mL
5 mM	0.4012 mL	2.0058 mL	4.0116 mL
10 mM	0.2006 mL	1.0029 mL	2.0058 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.01 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (5.01 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.01 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。